CLNN News and Press, Clene Inc. From 12/08/23

Clene (NASDAQ: CLNN) , together with its wholly owned subsidiary Clene Nanomedicine Inc., recently provided operating highlights for its amyotrophic lateral sclerosis (“ALS”) clinical program. “In August, Clene reported a 24-month long-term data cut from the open-label extens...

The 2023 Nobel Prize in Chemistry, awarded to Moungi G. Bawendi, Louis E. Brus, and Aleksey Yekimov for their efforts in discovering and synthesizing quantum dots, recognizes the power of nanotechnology Nanoscience is the study of structures and molecules whose sizes range between 1 and 100 nm,...

Clene’s (NASDAQ: CLNN) wholly owned subsidiary Clene Nanomedicine Inc. and its collaborators, Columbia University and Synapticure, recently received a four-year grant totaling $45.1 million. The grant will support an Expanded Access Protocol (“EAP”) study investigating the s...

A study recently published in the “ Scientific Reports ” journal has found a potential link between Parkinson’s, strokes and the onset of heart disease. Researchers behind the study used a two-sample Mendelian randomization analysis to find links associations between cardio...

Clene is focused on developing and commercializing novel clean-surfaced nanotechnology (“CSN(R)”) therapeutics The company utilizes an electro-crystallization nanotherapeutics platform, which results in nanocrystals that exhibit catalytic activities multiple times higher than nume...

Clene recently released its financial results for the third quarter ended September 30, 2023, and provided recent operating highlights for its ALS clinical program The ALS clinical program includes two independent studies evaluating the safety and efficacy of the company’s lead investiga...

Multiple sclerosis is a chronic illness that affects an individual’s brain and spinal cord, resulting in problems moving one’s arms or legs, issues with vision, and problems with balance or sensation.  While the cause of this disease is still not known, researchers theorize th...

Clene, a company targeting the treatment of neurodegenerative diseases that severely impact people’s lives, is currently focusing on amyotrophic lateral sclerosis (“ALS”) alongside other neurodegenerative diseases The company’s wholly owned subsidiary, Clene Nanomedi...

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., today released its third quarter 2023 financial results and provided recent operating highlights for its ALS clinical program. Among the highlights, the company repo...

2023-11-07 08:30:18 ET More on Clene Clene gains after $45M federal grant to study lead asset in ALS Seeking Alpha’s Quant Rating on Clene Historical earnings data for Clene Financial information for Clene For further details see: Clene GAA...